ClinicalTrials.gg
Sign In

Ocular Hypertension clinical trials

The registry lists 659 studies for Ocular Hypertension across more than 10 countries. 48 are recruiting or about to start. 45 of them are mainly about Ocular Hypertension (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 6 narrower conditions too, such as Glaucoma: 2,223 studies, 315 open.

ClinicalTrials.gov finds 2,323 studies for Ocular Hypertension. How that becomes 659 here

This page counts the studies the registry files under Ocular Hypertension, and those it files under no condition that list Ocular Hypertensionthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 2,323Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −1,503Filed under a narrower condition, counted on its own pageGlaucoma 1,045 · Glaucoma, Open-Angle 334 · Glaucoma, Angle-Closure 49 · Hydrophthalmos 27 · Glaucoma, Neovascular 25 · Low Tension Glaucoma 22
  3. −161Match it another way9 name it in the title and 152 by a synonym or other text the search reads.
  4. 659The count on this page4 of them list Ocular Hypertension in their own words; the registry filed them under no condition.

Get an email when these change. Save the Ocular Hypertension studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
485
Status unknown
49
Recruiting
36
Terminated
34
Withdrawn
24
Active, not recruiting
17

Phase

Phase 3
162
Phase 2
147
Phase 4
125
Phase 1
61

Where

United States
300
Canada
38
Germany
26
United Kingdom
26
Italy
23
Japan
22

Who runs them

Alcon Research (106) · Allergan (74) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (24) · Aerie Pharmaceuticals (22) · Glaukos Corporation (17) · Santen Pharmaceutical Co., Ltd. (13) · Mati Therapeutics Inc. (12) · Santen Inc. (12)

What is being tested here

Drugs under test in Ocular Hypertension studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Latanoprost21552
Bimatoprost21445
Netarsudil2616
Bimatoprost Ophthalmic Solution214
Travoprost12057
Eplerenone101
Ketorolac101
Drugs, Investigational101
Brinzolamide01434
Timolol0827

Drug classes tested here Beta blockers 40 · Corticosteroids 3

Coming up

11phase 3 studies under way
22studies finish main data collection within a year4 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 36 Ocular Hypertension studies recruiting now, 31 (86%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (3%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 4 (11%) take healthy volunteers.

Recruiting studies that take each age, of 36
AgeWomenMen
101 (3%)1 (3%)
1829 (81%)29 (81%)
3033 (92%)33 (92%)
4035 (97%)35 (97%)
5036 (100%)36 (100%)
6536 (100%)36 (100%)
7536 (100%)36 (100%)
8535 (97%)35 (97%)

Across all 659 studies, recruiting or not: 7% stop at 75 or younger and 4% at 65; 7% take children; 0% are for women only and 1% for men only; 12% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Ocular Hypertension studies take

Of 57 phase 3 interventional studies under Ocular Hypertension, half reached primary completion within 23 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 211 mo5–14 · 36 studies10 mo5–14 · 35 studies—
Phase 323 mo12–38 · 57 studies20 mo12–33 · 54 studies—
Phase 430 mo14–66 · 31 studies——
Interventional, no phase31 mo10–55 · 47 studies——
Observational25 mo9–62 · 27 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Newly registered1

Studies

Recruiting first, then most recently updated. Showing 50 of 659. Browse all 659 → or search them.